Navigation Links
Takeda's New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
Date:9/4/2013

believed to be reasonable, though they are inherently uncertain and difficult to predict. Investors are cautioned not to unduly rely on such forward-looking statements.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Some of these risks and uncertainties include, but are not limited to, (1) the economic circumstances surrounding Takeda's business, including general economic conditions in Japan, the United States and worldwide; (2) competitive pressures and developments; (3) applicable laws and regulations; (4) the success or failure of product development programs; (5) actions of regulatory authorities and the timing thereof; (6) changes in exchange rates; (7) claims or concerns regarding the safety or efficacy of marketed products or product candidates in development; and (8) integration activities with acquired companies.

The forward-looking statements contained in this press release speak only as of the date of this press release, and Takeda undertakes no obligation to revise or update any forward-looking statements to reflect new information, future events or circumstances after the date of the forward-looking statement. If Takeda does update or correct one or more of these statements, investors and others should not conclude that Takeda will make additional updates or corrections.


'/>"/>
SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
2. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
3. New Data for Abbotts Investigational High Sensitive Troponin Test Shows It May Help Doctors Predict Heart Attack Risk
4. Grifols Implements Its First Automated Inventory Management Carousel System for Investigational Pharmacies at Emory University
5. Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
6. Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
7. Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function
8. Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
9. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
10. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
11. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- ResMed Inc. (NYSE: RMD ) today announced results ... June 30, 2014.  Revenue for the quarter was $415.2 million, ... 1 percent decrease on a constant currency basis). Net income ... the quarter ended June 30, 2013. Diluted earnings per share ... compared to the quarter ended June 30, 2013.  ...
(Date:7/31/2014)... FRANCISCO, July 31, 2014 Nektar Therapeutics (Nasdaq: ... second quarter ended June 30, 2014. Cash ... $301.4 million as compared to $309.1 million at March 31, ... for Nektar as we look forward to significant milestones for ... Robin, President and Chief Executive Officer of Nektar. "The first ...
(Date:7/31/2014)... , July 31, 2014  Decision ... changes brought about by the Affordable Care ... and prescribing of pharmaceutical therapies. The ACA ... beneficiaries through new regulations and expanded access ... in the health exchanges—state-based marketplaces set up ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4
... ROCHESTER HILLS, Mich., Jan. 8 CSG/SportsCoatings,today announced ... will,be treated with its industry-leading antimicrobial coating, TurfAide(TM),in ... in 2007., The exponential increase in demand ... a 2007 report in the Journal of the ...
... of Phase 2 Clinical Trials in ... ... a privately held,biotechnology company developing treatments for metabolic diseases,announced today that it ... the use of very low dose glucagon, or DIO-901, in,the prevention of ...
Cached Medicine Technology:10 Million Square Feet of Turf Set to be Treated in 2008 in Response to MRSA Outbreaks Nationwide 2DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia 2
(Date:7/31/2014)... Ohio (PRWEB) July 31, 2014 United ... at 9 a.m. on Monday, September 15, with its ... Methodist Church, 3440 Shroyer Rd., Kettering, OH. Dr. ... Counseling in the Emma Toussant Chair will speak on ... , Dr. Justes’ teaching and research interests include pastoral ...
(Date:7/31/2014)... July 31, 2014 In today’s world, a ... to get. Snoring and sleep apnea (a medical problem where ... and their bed partners of the rest they need to ... the population snores and 20 million people in the United ... been diagnosed and treated; and of those treated, many cannot ...
(Date:7/31/2014)... Hook Your Ex, a system created by Steve Pratt, who discovered ... their partner, to the point of starvation, that they come back ... taught to hundreds of men and women across the country with ... , Shane Michaels agrees this simple trick is genius and can ... chance at getting back together with their ex. “I was ...
(Date:7/31/2014)... NEWwoodworks, fine woodworking group at New Energy ... a website dedicated to highlighting their craft and their ... handcrafted cabinetry, furniture, stairs , doors, and other ... for taking on the remarkable, challenging projects that few ... reclaimed wood, often using near extinct species such as ...
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 Dr. ... scientific meetings, “I love the experience of traveling and ... our centers in Southern California. We are now ... few years ago. It is our pleasure to communicate ... presentation about more efficient ways of performing FUE transplantation ...
Breaking Medicine News(10 mins):Health News:United Theological Seminary to Open 144th Year 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Hook Your Ex Review by Shane Michaels Exposes Steve Pratt And His New Method For Getting Back With The Ex 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 3Health News:Los Angles Hair Transplant Surgeon, Dr. Parsa Mohebi Inspires Doctors at Global Conferences to Adopt His Novel Method in FUE Hair Transplantation 2
... Mich. - A cancer diagnosis affects more than just the ... Michigan Comprehensive Cancer Center finds spouses report similar physical and ... study found that what really impacted emotional distress - among ... was newly diagnosed, facing a recurrence or living with advanced ...
... Board established; Former URAC CEO joins company along with ... Chief Medical Officer, ... of key senior management leaders to head the,growing healthcare consulting and technology ... and CEO; -- Joel V. Brill, MD, AGAF FASGE FACG ...
... research that aligns patients and treatments., ... The,H. Lee Moffitt Cancer Center & ... health enterprise platform, to aid in its,development ... be used,to assimilate large quantities of diverse ...
... MEDIA, Pa., Sept. 20 Synova Healthcare Group,Inc. (OTC ... sale,of approximately $3.3 million in aggregate notional principal amount ... September 19, 2012,and related common stock purchase warrants. This ... private placement of notes and warrants in the,aggregate notional ...
... 2007 Breihan Bridgewater suffers from emphysema. He sleeps on ... it feels like theres a boulder resting on his chest. ... prostate cancer, the thought of undergoing surgery or having to ... treatments left him with an uneasy feeling and a ...
... is leading cause of inherited mental retardation , , THURSDAY, ... defect might be a target for the treatment of ... researchers report. , The discovery in rats provides an ... condition changes the way brain cells communicate, according to ...
Cached Medicine News:Health News:Cancer patients, spouses report similar emotional distress, U-M study finds 2Health News:Schooner Healthcare Services, LLC Announces New Leadership Team 2Health News:Moffitt Selects Microsoft's Azyxxi to Help Drive Personalized Cancer Treatment 2Health News:Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants 2Health News:Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants 3Health News:Radiation therapy technique reduces length of prostate cancer treatment 2Health News:Radiation therapy technique reduces length of prostate cancer treatment 3Health News:Brain Defect Helps Drive Fragile X Syndrome 2Health News:Brain Defect Helps Drive Fragile X Syndrome 3
... Final Flexion Wraps restore full PIP joint ... when lost due to arthritic changes. Unparalleled ... material hugs the finger to prevent slipping ... motion. One size. Sold in packages of ...
One splint does it all....
... of minor knee pain like arthritis, tendonitis ... with the motion of the knee, applying ... tendon and assisting in the relief of ... with high density foam padding molds itself ...
... braces are designed to provide comfortable stabilization ... and versatile, ROM braces are an easy ... The braces are extremely patient-friendly, too. , ... hinges that allow you to restrict extension ...
Medicine Products: